Patents by Inventor Bruno Tocque
Bruno Tocque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140030319Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Inventors: BRUNO TOCQUE, BOHDAN WASLYK, MARIE-CHRISTINE DUBS-POTERSZMAN
-
Patent number: 8003375Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: GrantFiled: November 19, 2009Date of Patent: August 23, 2011Assignee: ExonHit Therapeutics S.A.Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Patent number: 7884082Abstract: A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.Type: GrantFiled: April 14, 2003Date of Patent: February 8, 2011Assignee: Aventis Pharma SAInventor: Bruno Tocque
-
Publication number: 20100144555Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: December 17, 2009Publication date: June 10, 2010Applicant: ExonHit TherapeuticsInventors: Bruno TOCQUE, Laurent Bracco, Florence Edon, Fabien Schweighoffer
-
Publication number: 20100144550Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: November 19, 2009Publication date: June 10, 2010Applicant: Exonhit TherapeuticsInventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20090264301Abstract: The present invention concerns new compositions and methods for the detection of pathological events. It more specifically concerns methods for the detection in vitro of the presence of a pathology or a pathological event in a subject, comprising taking a sample of blood cells from the subject and determining, in this sample, the presence of blood cells presenting a physiological state characteristic of the pathology. The invention also concerns the tools, kits and compositions for the implementation of such methods, as well as their uses in the field of human and animal health, or in experimental research for example.Type: ApplicationFiled: June 29, 2009Publication date: October 22, 2009Applicant: ExonHit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Publication number: 20080311608Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.Type: ApplicationFiled: January 10, 2007Publication date: December 18, 2008Inventors: Bruno Tocque, Bohdan Wasylyk, Marie-Christine Dubs-Poterszman
-
Publication number: 20050209177Abstract: A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.Type: ApplicationFiled: April 14, 2003Publication date: September 22, 2005Inventor: Bruno Tocque
-
Patent number: 6881571Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: GrantFiled: March 11, 1999Date of Patent: April 19, 2005Assignee: Exonhit Therapeutics S.A.Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20040209834Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.Type: ApplicationFiled: December 1, 2003Publication date: October 21, 2004Inventors: Bruno Tocque, Bohdan Wasylyk, Marie-Christine Dubs-Poterszman
-
Publication number: 20040191828Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: April 28, 2004Publication date: September 30, 2004Inventors: Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
-
Publication number: 20040127437Abstract: A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.Type: ApplicationFiled: April 14, 2003Publication date: July 1, 2004Inventor: Bruno Tocque
-
Publication number: 20030165931Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.Type: ApplicationFiled: October 30, 2002Publication date: September 4, 2003Inventors: Bruno Tocque, Laurent Bracco, Florence Edon, Fabien Schweighoffer
-
Patent number: 6544948Abstract: A polypeptide derivative of p62 having at least one deletion of at least one amino acid between amino acids 145 to 247 of p62, where the derivative inhibits signals transduced by ras.Type: GrantFiled: November 25, 1997Date of Patent: April 8, 2003Assignee: Aventis Pharma S.A.Inventors: Fabien Schweighoffer, Bruno Tocque
-
Publication number: 20030059788Abstract: The present invention describes new methods for the determination of the potential toxicity of test compounds, as well as the kits and tools for the implementation of these methods. The invention also describes methods for generating nucleic acid sequences that can be used as genetic markers of toxicity. The invention is based in particular on the creation of differential nucleic acid banks characteristic of situations in which cell viability and/or proliferation are deregulated, and on the demonstration that these banks can be used to evaluate the toxicity profile of compounds with reliability and high sensitivity. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile of compounds involved in drug development and/or in pharmaceutical compositions.Type: ApplicationFiled: August 2, 2002Publication date: March 27, 2003Inventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Publication number: 20030060432Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.Type: ApplicationFiled: March 23, 1998Publication date: March 27, 2003Inventors: BRUNO TOCQUE, BOHDAN WASYLYK, MARIE-CHRISTINE DUBS-POTERSZMAN
-
Patent number: 6509153Abstract: The present invention describes new methods for the determination of the potential toxicity of test compounds, as well as the kits and tools for the implementation of these methods. The invention also describes methods for generating nucleic acid sequences that can be used as genetic markers of toxicity. The invention is based in particular on the creation of differential nucleic acid banks characteristic of situations in which cell viability and/or proliferation are deregulated, and on the demonstration that these banks can be used to evaluate the toxicity profile of compounds with reliability and high sensitivity. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile of compounds involved in drug development and/or in pharmaceutical compositions.Type: GrantFiled: December 8, 1999Date of Patent: January 21, 2003Assignee: Exonhit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Patent number: 6372432Abstract: The present invention concerns new compositions and methods for the detection of pathological events. It more specifically concerns methods for the detection in vitro of the presence of a pathology or a pathological event in a subject, comprising taking a sample of blood cells from the subject and determining, in this sample, the presence of blood cells presenting a physiological state characteristic of the pathology. The invention also concerns the tools, kits and compositions for the implementation of such methods, as well as their uses in the field of human and animal health, or in experimental research for example.Type: GrantFiled: December 8, 1999Date of Patent: April 16, 2002Assignee: Exonhit Therapeutics SAInventors: Bruno Tocque, Laurent Bracco, Fabien Schweighoffer
-
Publication number: 20010021395Abstract: A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.Type: ApplicationFiled: March 26, 2001Publication date: September 13, 2001Inventor: Bruno Tocque
-
Patent number: RE37952Abstract: The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.Type: GrantFiled: August 15, 2000Date of Patent: December 31, 2002Assignee: Aventis Pharma S.A.Inventors: Fabien Schweighoffer, Bruno Tocque